Quantifying, Visualizing, and Monitoring Lead Optimization.

Although lead optimization (LO) is by definition a process, process-centric analysis and visualization of this important phase of pharmaceutical R&D has been lacking. Here we describe a simple statistical framework to quantify and visualize the progression of LO projects so that the vital signs of LO convergence can be monitored. We refer to the resulting visualizations generated by our methodology as the "LO telemetry" of a project. These visualizations can be automated to provide objective, holistic, and instantaneous analysis and communication of LO progression. This enhances the ability of project teams to more effectively drive LO process, while enabling management to better coordinate and prioritize LO projects. We present the telemetry of five LO projects comprising different biological targets and different project outcomes, including clinical compound selection, termination due to preclinical safety/tox, and termination due to lack of tractability. We demonstrate that LO progression is accurately captured by the telemetry. We also present metrics to quantify LO efficiency and tractability.

[1]  Abhyuday Mandal,et al.  Identifying Promising Compounds in Drug Discovery: Genetic Algorithms and Some New Statistical Techniques. , 2007 .

[2]  R. Hamatake,et al.  Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound. , 2014, Journal of medicinal chemistry.

[3]  Claude E. Shannon,et al.  Prediction and Entropy of Printed English , 1951 .

[4]  G. Derringer,et al.  Simultaneous Optimization of Several Response Variables , 1980 .

[5]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[6]  R. Hamatake,et al.  Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase. , 2014, Journal of medicinal chemistry.

[7]  R. Hamatake,et al.  Preclinical Characterization of GSK2336805, a Novel Inhibitor of Hepatitis C Virus Replication That Selects for Resistance in NS5A , 2013, Antimicrobial Agents and Chemotherapy.

[8]  J Willem M Nissink,et al.  Analyzing compound and project progress through multi-objective-based compound quality assessment. , 2013, Future medicinal chemistry.

[9]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[10]  Theodore T. Allen,et al.  An alternative desirability function for achieving ‘six sigma’ quality , 2003 .

[11]  N. Meanwell,et al.  Introduction to hepatitis C virus (HCV) therapies special thematic issue. , 2014, Journal of medicinal chemistry.

[12]  F. Mosteller,et al.  Understanding robust and exploratory data analysis , 1985 .

[13]  R. Esteban,et al.  Epidemiology of hepatitis C virus infection. , 1993, Journal of hepatology.

[14]  C. Moore,et al.  Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents. , 2014, Journal of medicinal chemistry.

[15]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[16]  William T. Scherer,et al.  "The desirability function: underlying assumptions and application implications" , 1998, SMC'98 Conference Proceedings. 1998 IEEE International Conference on Systems, Man, and Cybernetics (Cat. No.98CH36218).

[17]  N. Meanwell Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. , 2011, Chemical research in toxicology.

[18]  Nate Silver,et al.  The signal and the noise : why so many predictions fail but some don't , 2012 .

[19]  Kwang-Jae Kim,et al.  Expected Desirability Function: Consideration of Both Location and Dispersion Effects in Desirability Function Approach , 2007 .

[20]  John J. Peterson A Posterior Predictive Approach to Multiple Response Surface Optimization , 2004 .

[21]  D. J. Price,et al.  Imidazo[1,2-a]pyridines That Directly Interact with Hepatitis C NS4B: Initial Preclinical Characterization. , 2012, ACS medicinal chemistry letters.

[22]  A. Hopkins,et al.  The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.

[23]  D. J. Price,et al.  Hepatitis C replication inhibitors that target the viral NS4B protein. , 2014, Journal of medicinal chemistry.